Groupama Asset Managment Takes $1.34 Million Position in Edwards Lifesciences Corporation $EW

Groupama Asset Managment purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 16,690 shares of the medical research company’s stock, valued at approximately $1,337,000.

A number of other large investors have also modified their holdings of the company. Segall Bryant & Hamill LLC acquired a new position in Edwards Lifesciences during the 1st quarter valued at about $1,711,000. CTC Alternative Strategies Ltd. bought a new position in Edwards Lifesciences in the 1st quarter worth about $328,000. Vestor Capital LLC increased its stake in shares of Edwards Lifesciences by 55.2% in the first quarter. Vestor Capital LLC now owns 2,940 shares of the medical research company’s stock valued at $235,000 after purchasing an additional 1,046 shares during the period. J. Derek Lewis & Associates Inc. increased its stake in shares of Edwards Lifesciences by 145.1% in the first quarter. J. Derek Lewis & Associates Inc. now owns 9,290 shares of the medical research company’s stock valued at $744,000 after purchasing an additional 5,499 shares during the period. Finally, Western Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $72,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.9%

Shares of NYSE:EW opened at $86.17 on Friday. The company has a 50 day moving average of $87.91 and a 200-day moving average of $83.89. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The firm has a market cap of $49.62 billion, a P/E ratio of 49.52, a P/E/G ratio of 2.16 and a beta of 0.86. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter last year, the business earned $0.67 earnings per share. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $83.98, for a total value of $85,575.62. Following the sale, the vice president owned 33,682 shares of the company’s stock, valued at approximately $2,828,614.36. The trade was a 2.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 44,558 shares of company stock valued at $3,770,939. 0.31% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Evercore reiterated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Citigroup raised their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $87.00 to $101.00 in a research note on Friday, July 24th. BTIG Research boosted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.